BNTX241220C80000
- 32.24
- 0.000.00%
BioNTech Newsroom
CCORF Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $171.44
BioNTech Price Target Raised to $171.44/Share From $171.00 by Canaccord Genuity
BioNTech Is Maintained at Buy by Canaccord Genuity
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $122 to $171.44
BioNTech SE (BNTX) Gets a Buy From Deutsche Bank
Promising Potential of BioNTech's BNT327 in Treating Triple-Negative Breast Cancer Drives Buy Rating
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122
BioNTech Analyst Ratings
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH) and BioNTech SE (BNTX)
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
TD Cowen Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $122
BioNTech SE (BNTX) Receives a Hold From TD Cowen
J.P. Morgan Releases a Hold Rating on BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Remains a Buy on BioNTech SE (BNTX)
Evercore ISI Group Upgrades BioNTech to Outperform, Raises Price Target to $125
Berenberg Bank Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $130
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145